Early Outcomes and the Virological Effect of Delayed Treatment Switching to Second-Line Therapy in An Antiretroviral Roll-Out Programme in South Africa

Abstract

Background

More patients in resource-limited settings are starting second-line antiretroviral treatment (ART) following first-line ART failure. We aimed to describe predictors of lack of virological suppression in HIV-infected patients on second-line ART in a roll-out programme in South Africa.

Methods

A retrospective analysis was performed on an adult HIV treatment cohort who started second-line ART (lopinavir/ritonavir, didanosine and zidovudine) after virological failure of first-line ART (two consecutive HIV RNA>1,000 copies/ml). Predictors of week 24 lack of suppression (HIV RNA>400 copies/ml) on second-line ART were determined by bivariate analysis where missing equals failure. A multivariable model that adjusted for gender, age and time to ART switch was used. We tested these findings in sensitivity analyses defining lack of suppression at week 24 as HIV RNA>1,000 and >5,000 copies/ml.

Results

Of 6,339 patients on ART, 202 started second-line ART. At week 24, an estimated 41% (95% CI 34–47) did not achieve virological suppression. Female sex (adjusted OR 2.25, 95% CI 1.03–4.88) and time to ART switch (adjusted OR 1.07, 95% CI 1.01–1.14 for each additional month) increased the risk of lack of virological suppression. Age, CD4⁺ T-cell count and HIV RNA at second-line ART initiation did not predict this outcome. In multivariate models, these findings were insensitive to the definition of lack of virological suppression.

Conclusions

A substantial number of HIV-infected patients do not achieve virological suppression by week 24 of second-line ART. Women and patients with delayed start of second-line ART after first-line ART failure were at an increased risk of lack of virological suppression.

References

World Health Organization. Progress on global access to HIV antiretroviral therapy a report on ‘3x5′ and beyond. Geneva: World Health Organization 2006. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/progreport2006_en.pdf.

World Health Organization. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2008. Geneva WHO

UNICEF, UNAIDS

2008. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/towards_universal_access_report_2008.pdf.

World Health Organization. Prioritizing second-line antiretroviral drugs for adults and adolescents: a public health approach. Geneva: World Health Organization, HIV Department 2007. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/meetingreports/Second_Line_Antiretroviral.pdf.

Gallant

J.E.

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries. Clin Infect Dis 2007; 44: 453–455.

Boyd

M.A.

, Cooper

D.A.

Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research. AIDS 2007; 21 Suppl 4: S55–S63.

Elliott

J.H.

, Lynen

, Calmy

Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. AIDS 2008; 22: 2053–2067.

Long

, Fox

, Sanne

, Rosen

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS 2010; 24: 915–919.

Humphreys

E.H.

, Chang

L.W.

, Harris

Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev 2010; 6: CD006517.

Petersen

M.L.

, van der Laan

M.J.

, Napravnik

Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008; 22: 2097–2106.

10.

Riddler

S.A.

, Jiang

, Tenorio

A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115. Antivir Ther 2007; 12: 531–541.

11.

Lawn

S.D.

, Myer

, Orrell

, Bekker

L.G.

, Wood

Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19: 2141–2148.

12.

Bekker

L.G.

, Myer

, Orrell

, Lawn

, Wood

Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Gugulethu, South Africa. S Afr Med J 2006; 96: 315–320.

13.

Lawn

S.D.

, Myer

, Harling

Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43: 770–776.

14.

Orrell

, Harling

, Lawn

S.D.

Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12: 83–88.

15.

Cornell

, Myer

, Kaplan

, Bekker

L.G.

, Wood

The impact of gender and income on survival and retention in a South African antiretroviral therapy programme. Trop Med Int Health 2009; 14: 722–731.

16.

World Health Organization. Treat 3 million by 2005: scaling up antiretroviral therapy in resource limited settings. A public health approach: World Health Organization; 2004. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/prev_care/en/arvrevision2003en.pdf.

17.

Department of Health South Africa. National antiretroviral treatment guidelines, Jacana 2004. (Accessed 11 May 2011.) Available from http://www.hst.org.za/uploads/files/sa_ART_Guidelines1.pdf.

18.

Orrell

, Bekker

L.G.

, Wood

Adherence to antiretroviral therapy – achievable in the South African context?

S Afr Med J 2001; 91: 483–484.

19.

World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva; 2009. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf.

20.

World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2006 revision). Geneva; 2006. (Accessed 11 May 2011.) Available from http://www.who.int/hiv/pub/guidelines/artadultguidelines.pdf.

21.

Gupta

R.K.

, Pillay

HIV resistance and the developing world. Int J Antimicrob Agents 2007; 29: 510–517.

22.

Seyler

, Adje-Toure

, Messou

Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 2007; 21: 1157–1164.

23.

Pujades-Rodríguez

, O'Brien

, Humblet

, Calmy

Second-line antiretroviral therapy in resource-limited settings: the experience of Medecins Sans Frontieres. AIDS 2008; 22: 1305–1312.

24.

ART-LINC of IeDEA Study Group, Keiser O, Tweya H, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009; 23: 1867–1874.

25.

Keiser

, Tweya

, Braitstein

Mortality after failure of antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 2010; 15: 251–258.

26.

Miller

C.M.

, Ketlhapile

, Rybasack-Smith

, Rosen

Why are antiretroviral treatment patients lost to follow-up? A qualitative study from South Africa. Trop Med Int Health 2010; 15 Suppl 1: 48–54.

27.

Pasquet

, Messou

, Gabillard

Impact of drug stock-outs on death and retention to care among HIV-infected patients on combination antiretroviral therapy in Abidjan, Cote d'Ivoire. PLoS ONE 2010; 5: e13414.

28.

Chalker

, Wagner

, Tomson

Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators. J Acquir Immune Defic Syndr 2010; 53: 159–161.

29.

Maartens

, Decloedt

, Cohen

Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009; 14: 1039–1043.

30.

L'homme

R.F.

, Nijland

H.M.

, Gras

Clinical experience with the combined use of lopinavir/ritonavir and rifampicin. AIDS 2009; 23: 863–865.

31.

Orrell

, Bangsberg

D.R.

, Badri

, Wood

Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17: 1369–1375.

32.

Charles

, Noel

, Leger

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals. Bull World Health Organ 2008; 86: 970–977.

33.

Fox

M.P.

, Ive

, Long

, Maskew

, Sanne

High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53: 500–506.

34.

Murphy

R.A.

, Sunpath

, Lu

Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24: 1007–1012.

35.

Castelnuovo

, John

, Lutwama

Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity. J Int Assoc Physicians AIDS Care (Chic) 2009; 8: 52–59.

36.

Hosseinipour

M.C.

, Kumwenda

J.J.

, Weigel

Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. HIV Med 2010; 11: 510–518.

37.

White

K.L.

, Chen

J.M.

, Feng

J.Y.

The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11: 155–163.

38.

Sungkanuparph

, Manosuthi

, Kiertiburanakul

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447–452.

39.

Coetzee

, Hildebrand

, Boulle

Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18: 887–895.

40.

Orrell

, Walensky

R.P.

, Losina

HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14: 523–531.

41.

Gupta

, Hill

, Sawyer

A.W.

, Pillay

Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47: 712–722.

42.

DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006; 20: 1391–1399.

43.

Marconi

V.C.

, Sunpath

, Lu

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46: 1589–1597.

44.

Hosseinipour

M.C.

, van Oosterhout

J.J.

, Weigel

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23: 1127–1134.

45.

Muula

A.S.

, Ngulube

T.J.

, Siziya

Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health 2007; 7: 63.

46.

Braitstein

, Brinkhof

M.W.

, Dabis

Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367: 817–824.

47.

ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), Keiser O, Anastos K, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13: 870–879.